CAR T Cell Therapy Market Expansion to be Persistent During 2018 2026

Posted by rushi007 on April 26th, 2019

CAR-T cell therapy is a novel immunotherapy that helps to treat various types of cancers. CAR-T cells are genetically engineered cell receptors that are attached to the T-cells of the cancer patients and infused through the blood stream that activates immune system to kill the cancer causing cells in the body. The T-cells injected into the patient’s body aids in reducing the risk of recurrence of tumor and thus, acts as a cure treatment for patients suffering with blood cancer. The CAR-T cell therapy is a solution to overcome the disease progression, identify the cancer causing cells, and kill them using body’s own immune system and defense mechanism.

 

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/102

 

Side Effects Restraining Growth

Major side effects encountered are cytokine-release syndrome: excess cytokine-release after T-cell activation, causes delirium, low blood pressure and poor lung oxygenation; B-cell aplasia where normal B-cells are destroyed by antigens though long-term effects have not been found; Tumor lysis syndrome, a metabolic complication arising due to breakdown of dying cells but can be controlled by supportive therapy. Potential solutions such as introduction of suicide-gene T-cells causing death of the engineered T-cells after the required period help negate side effects. Manufacturing-infrastructure, personalized- approach of the therapy, side-effect handling: all these factors attach an exorbitant price tag to this treatment. Affordability, a big limitation but longevity of the treatment and broader applicability to all age-groups are significant add-ons.

 

Product Launches In Pipeline Expected To Boost The Market

Currently, CAR T cells therapy is available only to patients on clinical trial, though with clinical evaluation growing exponentially two companies Novartis International AG and Kite Pharma Inc are in plans to register their respective products, CTL019(anti-CD19) targeting lymphoblastic leukaemia in paediatrics and Kte-C19(anti-CD19) with B-cell lymphoma, in 2017. Juno Therapeutics hit a roadblock in launching JCAR015, a product targeting adult patients due to death of five patients under clinical trial due to therapy-induced cerebral edema. Recently, Novartis shut its cell and gene therapy unit, apparently an unexpected move.

  

Global Key Players:

Key companies covered as a part of this study include Thermo Fisher Scientific, Inc., GE Healthcare, Corning, Inc., Sigma - Aldrich Corporation, VWR International, LLC, Merck KGAA, Becton, Dickinson and Company, Eppendorf AG, Sartorius AG and Lonza Group AG

 

Market Dynamics

CAR-T cell therapy is expected to be an important development in cancer treatment and therapeutics industry due to its cost efficiency. Moreover, rising incidence of cancer is leading to high demand for its treatment. According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases would be observed worldwide. Moreover, introduction of new therapies into the market is further expected to bolster growth of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug Administration granted marketing approval to Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma. However, risks of side effects resulting in various neurological disorders is expected to hinder growth of the global CAR-T cell therapy market.

 

Browse Research Report At: https://www.coherentmarketinsights.com/market-insight/car-t-cell-therapy-market-102

 

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Like it? Share it!


rushi007

About the Author

rushi007
Joined: February 13th, 2019
Articles Posted: 397

More by this author